ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Old 06-24-2019, 01:01 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is offline
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 4,052
Default Emerging Evidence on the Selective Use of AHSCT in MS

Compelling evidence suggests that autologous hematopoietic stem cell transplantation may be useful in subgroups of patients with relapsing-remitting multiple sclerosis that’s considered aggressive, highly active, and treatment refractory.

By Gloria Arminio Berlinski, MS
Reviewed by Aaron Miller, MD, Professor of Neurology, Icahn School of Medicine at Mount Sinai and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY

Multiple sclerosis (MS) is a chronic inflammatory disease thought to evolve from attacks by autoreactive lymphocytes on the central nervous system’s myelin sheath peptides.1 Given this widely accepted theory of MS pathophysiology, researchers have been investigating autologous hematopoietic stem cell transplantation (AHSCT) as a treatment alternative to conventional therapy, with the first reported AHSCT-MS study being initiated in 1995. Accumulating data—mostly from small, open-label studies, including just a few with long-term follow-up—point to this procedure as primarily benefiting subgroups of patients with aggressive and highly active relapsing-remitting MS (RRMS) that’s unresponsive to established therapies.

Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 10:46 AM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.